Kamada (Kamada) FCF Margin % : 6.69% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Kamada FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kamada's Free Cash Flow for the three months ended in Dec. 2023 was $2.4 Mil. Kamada's Revenue for the three months ended in Dec. 2023 was $36.4 Mil. Therefore, Kamada's FCF Margin % for the quarter that ended in Dec. 2023 was 6.69%.

As of today, Kamada's current FCF Yield % is -0.54%.

The historical rank and industry rank for Kamada's FCF Margin % or its related term are showing as below:

KMDA' s FCF Margin % Range Over the Past 10 Years
Min: -23.89 Med: -0.75 Max: 19.87
Current: -1.1

During the past 13 years, the highest FCF Margin % of Kamada was 19.87%. The lowest was -23.89%. And the median was -0.75%.

KMDA's FCF Margin % is ranked worse than
51.07% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs KMDA: -1.10

Kamada FCF Margin % Historical Data

The historical data trend for Kamada's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada FCF Margin % Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

19.87

10.22

-12.11

19.18

-1.08

Kamada Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															12.69	-12.92	2.06	-2.13	6.69

Competitive Comparison of Kamada's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kamada's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kamada's FCF Margin % falls into.

Kamada FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kamada's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.535	/	142.519
	=	-1.08 %

Kamada's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	2.436	/	36.432
	=	6.69 %

Kamada FCF Margin % Related Terms

Thank you for viewing the detailed overview of Kamada's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada (Kamada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

KMDA:Israel

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.